As part of Celgene’s (NASDAQ:CELG) deal with Juno Therapeutics (NASDAQ:JUNO), Celgene agreed to “purchase 9,137,672 shares of Juno’s common stock at $93.00 per share,” according to the press release.
If Celgene thinks Juno is worth $93 per share, why is Juno trading at a substantial discount to that price?
As I wrote previously on a Motley Fool message board, the short answer is: “Celgene doesn’t think Juno is worth $93 now.
Hey, check out all the research scientist jobs. Post your resume today!
